Clinical trial
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
NCT00113113 · Astex Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00113113 |
|---|---|
| Title | Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction |
| Official title | Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Rubitecan |
| Enrollment | 54 |
| Start date | Aug 1, 2001 |
| First posted | Jun 6, 2005 |
| Last update posted | Aug 2, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: